Kronos Bio, INC 8-K filings

Kronos Bio, Inc. has successfully completed its merger with Concentra Biosciences, LLC, becoming a wholly-owned subsidiary and leading to the delisting of its common stock from Nasdaq.

Kronos Bio, Inc. has announced the early termination of its Cambridge office and laboratory lease, effective June 30, 2025, leading to an estimated $18.2 million in aggregate cost savings, while also referencing an ongoing tender offer and merger.

Kronos Bio has entered into a definitive merger agreement with Concentra Biosciences, where Concentra will acquire Kronos Bio for $0.57 in cash per share plus a contingent value right (CVR).

Kronos Bio, Inc. terminated its office lease agreement for its corporate headquarters in San Mateo, California, effective April 30, 2025, resulting in a net payment of $1.4 million and an estimated savings of $0.2 million.

Kronos Bio reports its fourth quarter and full year 2024 financial results, including a net loss of $25.8 million for the quarter and $86.1 million for the year, while also evaluating strategic alternatives.

Kronos Bio has terminated its collaboration agreement with Genentech, transferring related assets and intellectual property in exchange for a one-time payment.

Kronos Bio is reducing its workforce by approximately 83% and transitioning its CEO as part of a strategic resource allocation and cost containment plan.

Kronos Bio has discontinued the development of istisociclib due to an unfavorable risk-benefit profile and is exploring strategic alternatives to maximize stockholder value.

Kronos Bio has been notified by Nasdaq that it is not in compliance with listing rules due to its stock price falling below $1.00 for 30 consecutive days.

Kronos Bio reported its second quarter 2024 financial results, provided a pipeline update, and announced the appointment of a new COO and CFO.

Kronos Bio held its 2024 Annual Meeting of Stockholders, electing three Class I Directors, approving executive compensation, and ratifying the selection of Ernst & Young LLP as its independent auditor.

Kronos Bio has appointed Deborah Knobelman as its new Chief Financial Officer and Chief Operations Officer, effective June 3, 2024, replacing Sandra Gardiner.

Kronos Bio announced its first quarter 2024 financial results, highlighting a cash runway into the second half of 2026 and progress in its clinical programs.

Kronos Bio announced progress in its clinical programs, including the advancement of KB-0742 and KB-9558, and reported its fourth-quarter and full-year 2023 financial results.

Kronos Bio is reducing its workforce by approximately 21% as part of a strategic cost-cutting initiative, expecting to incur around $0.6 million in related charges.

Kronos Bio has modified the dosing schedule for its KB-0742 clinical trial to increase patient exposure to the drug, with updated data expected in mid-2024 and expansion phase results in the first half of 2025.

Kronos Bio has announced the departure of three key executives, including the Chief Medical Officer, Chief Operating Officer, and Chief Scientific Officer, all effective February 16, 2024.